Tarsus Pharmaceuticals Inc
$ 67.24
-0.71%
17 Apr - close price
- Market Cap 2,881,993,000 USD
- Current Price $ 67.24
- High / Low $ 69.68 / 66.66
- Stock P/E N/A
- Book Value 8.07
- EPS -1.59
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.09 %
- ROE -0.23 %
- 52 Week High 85.25
- 52 Week Low 38.51
About
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
Analyst Target Price
$95.11
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-16 | 2025-11-04 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-09 | 2023-08-10 | 2023-05-09 |
| Reported EPS | -0.2 | -0.3 | -0.48 | -0.64 | -0.6 | -0.61 | -0.88 | -1.01 | -1.31 | -1.28 | -1.17 | -0.88 |
| Estimated EPS | -0.0836 | -0.35 | -0.38 | -0.63 | -0.8157 | -0.94 | -0.92 | -1.2 | -1.36 | -1.37 | -1.08 | -0.94 |
| Surprise | -0.1164 | 0.05 | -0.1 | -0.01 | 0.2157 | 0.33 | 0.04 | 0.19 | 0.05 | 0.09 | -0.09 | 0.06 |
| Surprise Percentage | -139.2344% | 14.2857% | -26.3158% | -1.5873% | 26.4435% | 35.1064% | 4.3478% | 15.8333% | 3.6765% | 6.5693% | -8.3333% | 6.383% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.25 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TARS
2026-04-12 21:09:53
This article analyzes Tarsus Pharmaceuticals Inc. (TARS), highlighting strong market sentiment and a significant risk-reward setup. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strength, support, and resistance levels for TARS.
2026-04-06 17:40:04
Tarsus Pharmaceuticals has initiated a Phase 2 trial for TP-05, an oral prophylactic for Lyme disease, marking the company's expansion beyond eye care into infectious disease prevention. This development could transform its investment narrative by diversifying its product pipeline beyond its existing commercial asset, XDEMVY, while also leveraging its lotilaner platform. The company's financial projections indicate significant revenue and earnings growth by 2028, with some analysts forecasting even higher figures.
2026-04-06 09:11:15
Capricorn Fund Managers Ltd significantly reduced its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 90.8% in the fourth quarter, selling 218,038 shares. This divestment leaves them with 21,982 shares valued at approximately $1.8 million. Several company insiders have also been net sellers, with the CEO and General Counsel selling shares totaling over $1 million, while analysts maintain a "Moderate Buy" consensus rating with an average target price of $91.83.
2026-04-06 07:39:37
Tarsus Pharmaceuticals has initiated its Phase 2 Calliope trial for TP-05, an oral prophylactic for Lyme disease, marking a diversification beyond its eye-care focus. This development could substantially alter Tarsus's investment profile, potentially reducing its dependence on XDEMVY sales and funding future pipeline projects. While the trial is an early-stage catalyst, investors will need to weigh its potential against the continued importance of XDEMVY's performance and market competition.
2026-04-03 17:39:38
Tarsus Pharmaceuticals has initiated a Phase 2 trial for TP-05, an oral candidate for Lyme disease, drawing attention to its valuation. Despite recent progress and a strong multi-year stock performance, its share price has cooled from highs, leading to questions about whether it's an opportunity or if future growth is already priced in. While one narrative suggests it's 19.7% undervalued with a fair value of $87.50, another view based on its P/S ratio of 6.6x suggests a more cautious outlook compared to the industry average.
2026-04-03 09:09:54
JPMorgan Chase & Co. reduced its stake in Tarsus Pharmaceuticals, Inc. by 45.1%, selling 63,420 shares and now holding 77,190 shares valued at approximately $4.59 million. The article also notes significant insider selling, with a director and CEO collectively disposing of nearly 24,500 shares, and analysts maintaining a "Moderate Buy" rating with an average target price of $91.83 for TARS.
